Kairos Pharma Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company, has announced new findings regarding its investigational small molecule GITR ligand agonist, KROS101. Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting in Chicago, the study highlights KROS101's potential as a cancer immunotherapy. The data indicate that KROS101 exhibits strong activity in enhancing the immune system and targeting tumor cells through its dual mechanism of action. The study demonstrated that KROS101 enhances T cell function by promoting proliferation and increasing cytotoxicity, while also reducing T reg-mediated suppression. The findings suggest that KROS101 is superior to the anti-GITR antibody TRX518 in several aspects, including T cell tumor infiltration and cytotoxicity. The company plans to continue studying KROS101 and engage with the medical and scientific communities regarding these findings.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。